Evidence map›Paper›PMID 33307998›Full record

Trial reportMultiple sclerosis (Houndmills, Basingstoke, England)2021

Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring.

Peter A Calabresi, Douglas L Arnold, Dipen Sangurdekar, Carol M Singh, Arman Altincatal, Carl de Moor, Bob Engle, Jaya Goyal, Aaron Deykin, Suzanne Szak and 3 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Multiple sclerosis (Houndmills, Basingstoke, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00906399 (A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a), which is not on this map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00906399 phase3completednot on this map

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis

TypeinterventionalSponsorBiogenRan2009 to 2013Enrolled1,516ConditionsRelapsing Multiple SclerosisArmsBIIB017 (peginterferon beta-1a), Placebo
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Review
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Neurofilaments contribution in clinic: state of the art.Frontiers in aging neuroscience · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Peter A CalabresiDepartment of Neurology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Douglas L ArnoldMontreal Neurological Institute, McGill University, Montreal, QC, Canada/NeuroRx, Montreal, QC, Canada.
Dipen SangurdekarBiogen, Cambridge, MA, USA.
Carol M SinghBiogen, Cambridge, MA, USA.
Arman AltincatalBiogen, Cambridge, MA, USA.
Carl de MoorBiogen, Cambridge, MA, USA.
Bob EngleBiogen, Cambridge, MA, USA.
Jaya GoyalBiogen, Cambridge, MA, USA.
Aaron DeykinBiogen, Cambridge, MA, USA.
Suzanne SzakBiogen, Cambridge, MA, USA.
Bernd C KieseierDepartment of Neurology, Medical Faculty, Heinrich Heine University, Dusseldorf, Germany/Biogen, Cambridge, MA, USA.
Richard A RudickBiogen, Cambridge, MA, USA.
Tatiana PlavinaBiogen, Cambridge, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo understand how longitudinal serum neurofilament light chain (sNfL) patterns can inform its use as a prognostic biomarker in multiple sclerosis (MS) and evaluate whether sNfL reflects MS disease activity and disease-modifying therapy usage.

methodsThis was a post hoc analysis of longitudinal data and samples from the ADVANCE trial (NCT00906399) of patients with relapsing-remitting MS (RRMS). sNfL was measured every 3 months for 2 years, then every 6 months for 4 years. Regression models explored how sNfL data predicted 4-year values of brain volume, expanded disability status scale score, and T2 lesions. sNfL levels were assessed in those receiving placebo, peginterferon beta-1a, and those with disease activity.

resultsBaseline sNfL was a predictor of 4-year brain atrophy and development of new T2 lesions. Clinical (

conclusionThese data support sNfL as a prognostic and disease-monitoring biomarker for RRMS.

Indexed as

Multiple Sclerosis, Relapsing-RemittingHumansMonitoring, PhysiologicNeurofilament ProteinsNeurofilament ProteinsBiomarkerbrain atrophymagnetic resonance imagingmultiple sclerosisprognosisserum neurofilament light chain

Identifiers

PMID33307998
PMCPMC8414824

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.